Search This Blog

Thursday, January 4, 2024

Florida Surgeon General Warns Against Using mRNA COVID Vaccines Over Possible Cancer Risk

 by Jacob Burg via The Epoch Times (emphasis ours),

Florida’s Surgeon General, Dr. Joseph Ladapo, is warning against any use of the Pfizer and Moderna COVID-19 mRNA vaccines citing cancer concerns.

Dr. Ladapo says a Canadian study found “billions to hundreds of billions” of DNA molecules per dose, exceeding guidelines set forth by the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO).

He sent a letter on Dec. 6, to the FDA Commissioner Dr. Robert Califf and the Centers for Disease Control and Prevention (CDC) Director Dr. Mandy Cohen outlining his concerns about the high presence of DNA molecules in the mRNA vaccines alongside lipid nanoparticles (LNPs) used to deliver medicine into human cells.

If LNPs are so effective at administering the vaccine’s medicine into human cells, Dr. Ladapo says he fears they will deliver the contaminant DNA molecules simultaneously.

He cites a 2007 guidance report from the FDA on the regulatory limits for DNA in vaccines, which indicated risks of affecting the human genes that transform healthy cells into cancerous cells.

The report also discusses the risk of how this integration of DNA in vaccines can lead to issues with the heart, brain, blood, kidney, liver, bone marrow, lung, ovaries, and testes, draining lymph nodes, spleen, and the vaccine’s administration and injection site.

“DNA integration poses a unique and elevated risk to human health, and to the integrity of the human genome, including the risk that DNA integrated into sperm or egg, gametes could be passed onto offspring of mRNA COVID-19 vaccine recipients.

If the risks of DNA integration have not been assessed for mRNA COVID-19 vaccines, these vaccines are not appropriate for use in human beings,” Dr. Ladapo said in a news release.

He is not calling for a widespread rejection of all vaccines and instead urges health care providers to prioritize non-mRNA COVID-19 vaccines and treatment while assessing research into overall vaccine risks.

Dr. Ladapo was in hot water in April 2023 after a public records request discovered edits he made to a state-commissioned survey on mRNA vaccines, garnering accusations of “exaggerating” the data to fit his position against giving COVID-19 vaccines to “healthy” children and adults of certain ages.

He defended the move as a scientific “revision” and felt justified in removing a certain data analysis from the original survey.

But others have raised concerns with the mRNA COVID-19 vaccines as well, including Dr. Eduardo Balbona, an internal medicine doctor from Jacksonville, Florida.

Dr. Balbona has been practicing for three decades and advocates for evidence-based medicine that emphasizes preventing disease and maintaining health with “education and a deliberative proactive approach to lifelong care.”

After receiving single or repeat doses of the mRNA vaccines, some of his patients experienced a host of different symptoms and felt “ill immediately afterward.”

In “some people, it takes a couple of weeks. So there [are] different patterns of injury. And I would say [for] some people, it’s almost an anaphylactic reaction.

They have the vaccine, and from that moment on, they’re just not well. Often ... they lose their blood pressure, or they have a crazy blood pressure. It either drops to 70 or goes to 200,” Dr. Balbona told The Epoch Times.

Several of his patients also developed posterior orthostatic tachycardia syndrome (POTS) which, according to the Cleveland Clinic, is a condition that “causes your heart to beat faster than normal when you transition from sitting or lying down to standing up.”

POTS is not easy to diagnose because several of its symptoms, including dizziness, fainting, chest pain, headaches, and heart palpitations, can occur over time despite resulting from a common cause.

There is currently no cure for POTS, although exercise, physical activity, and a cardiac rehabilitation program can be used as treatment.

Dr. Balbona also saw patients with increased blood pressure and others who had developed a hypercoagulable state, which is when the blood coagulates excessively in the absence of bleeding, according to the National Institutes of Health.

He was also concerned by the number of men in their late teens, 20s, and 30s who developed pulmonary embolisms without genetic predispositions or pre-existing health issues that would cause them.

A pulmonary embolism occurs when a fragment, most likely a blood clot, gets stuck in a lung artery and blocks the flow of blood, according to the Mayo Clinic.

Other patients developed myocarditis and pericarditis directly after receiving the vaccine, Dr. Balbona said.

According to the CDC, “myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the outer lining of the heart.”

The symptoms of myocarditis and pericarditis are chest pain, shortness of breath, and “feelings of having a fast beating, fluttering, or pounding heart.”

The CDC admits that some patients developed these conditions after receiving the mRNA COVID-19 vaccines but that cases are “rare” and that many heal on their own.

However, since the symptoms can mimic anxiety reactions, some patients might be unaware they have either myocarditis or pericarditis, making data collection difficult.

Dr. Balbona spoke with patients who went to hospitals with these symptoms and were turned away by nurses and doctors who told them the issues were psychological, possibly assuming the patients were anxious or experiencing acute panic attacks.

He also believes some who received the vaccines were given “blanks” instead of shots with active medicine inside. Dr. Balbona said he tested several patients after they received their shots, and they lacked COVID-19 antibodies, which should be present in the blood after vaccination.

Dr. Balbona believes some patients might have been vaccinated with just saline solution as a result of poor storage and handling of the vaccines themselves, which required cold storage at all times to prevent the destruction of the medicine inside.

Patients often tell him they’re worried about falling ill because of having had one or many COVID-19 vaccines.

So if you had the vaccine several years ago, and you feel fine, and you have no problems, you’re likely okay,” he added.

Dr. Balbona believes the research will eventually catch up with what he and other physicians are seeing while treating their patients.

“At some point—I think that point is long past due—these vaccines will be withdrawn from the market. They’re not safe. They’re harming people. They may be harming people in ways that are durable. The recent DNA contamination is very concerning for increasing risk of cancer,” he said.

However, despite the alleged cancer risks of using mRNA inside COVID-19 vaccines, he said, “the underlying technology is something that’s actually very remarkable.

mRNA technology was misused in the COVID pandemic,” he said. “It should not be given indiscriminately.

“It’s gene therapy; there’s no question of that. And it has the ability to do some remarkable things in terms of good in the right situation. If you can turn on and off a gene or a protein in a patient who has a very serious illness, that’s fine.

“That may be a fabulous tool in the future, but you have to disclose the risks and the benefits.”

Nanette Holt contributed to this report.

https://www.zerohedge.com/covid-19/florida-surgeon-general-warns-against-using-mrna-covid-vaccines-over-possible-cancer-risk

US Strike Kills Iran-Backed Leader In Baghdad Believed Behind Attacks On US Bases

by Dave DeCamp via AntiWar.com,

A US drone strike in Baghdad killed a senior militia leader on Thursday, marking another significant escalation that could lead to a full-blown regional war.

The strike killed Mushtaq Talib al-Saidi, also known as Abu Taqwa, a deputy commander of the Popular Mobilization Forces (PMF) operations in Baghdad. The PMF is a coalition of mostly Shia Iraqi militias that are part of the government’s security forces.

At least one other militia member was killed in the strike, which targeted a PMF base in Baghdad. Later on Thursday, the Pentagon confirmed it was responsible for the bombing.

The Pentagon claims Abu Taqwa was believed to be responsible for attacks on US bases in Iraq and Syria that started in October in response to US support for Israel’s onslaught in Gaza, but the US has not provided any evidence for the assertion.

The drone strike has enraged the Iraqi government, which condemned it as a "flagrant violation of the sovereignty and security of Iraq" and said it was "no different from a terrorist act."

The US has launched several rounds of airstrikes in Iraq since October, all of which have been strongly condemned by the government of Iraqi Prime Minister Mohammed Shia al-Sudani, the US’s supposed partner in the country.

Al-Sudani’s government has also condemned the attacks on US bases in Iraq but wants to work to find the perpetrators and strongly opposes the unilateral US airstrikes and extra-judicial killings.

Al-Sudani said last week that his government was "heading towards" ending the presence of foreign forces in Iraq, which includes 2,500 US troops.

Iraq’s parliament voted to expel US troops back in 2020 following the US drone strike that killed Iranian Gen. Qasem Soleimani and PMF leader Abu Mahdi al-Muhandis, but the US has refused to leave.

https://www.zerohedge.com/geopolitical/us-strike-kills-iran-backed-leader-baghdad-believed-behind-attacks-us-bases

Was "January 6" A Manufactured Crisis?

 

 

Depending on whom you ask, it was either "the darkest day in American history" or "a guided tour." To this day, the January 6 Capitol Riot remains one of the most divisive issues in American politics.


Conservative pundits like Tucker Carlson and Dinesh D'Souza point to lengthy prison sentences for nonviolent trespassers, the killing of Ashley Babbitt, and suspicious characters like Ray Epps as evidence of a burgeoning “police state” entrapping and imprisoning dissidents.

On the other hand, liberal pundits and never-Trumpers like MSNBC’s Joy Reid, Adam Kinzinger and Liz Cheney, believe Jan 6 was nothing short of an attempted coup by former president Donald Trump.

According to recent polling by the University of Chicago, 80% of Democrats believe Trump broke the law by inciting the Capitol riots, while roughly half of Republicans believe he did nothing wrong: 

Such divides have consequences.

On December 19, the Colorado Supreme Court — citing "clear and convincing" evidence that he engaged in an "insurrection" — ruled that “President Trump is disqualified from holding the office of President” and barred the state’s Secretary from including Trump’s name on the ballot for upcoming GOP primary elections.

This dispute over January 6 — and whether it was indeed an insurrection — may very well determine the next U.S. President.

The ZeroHedge "January 6" Debate

On the coming anniversary of January 6 (Saturday), ZeroHedge will present the second debate in our inaugural series aimed at bringing long-form dialogues back into the ideologically-siloed and echo-chambered media landscape.

We will host an in-depth discussion on the various aspects of that fateful day in 2021, allowing people with all perspectives a chance to present evidence and make their argument.

Our panel will include such media luminaries as Alex Jones, Darren Beattie, Glenn Greenwald on one side, and Ed and Brian Krassenstein, as well as YouTuber "Destiny" on the other.

We hope to get closer to the truth of what happened on that day and get to the bottom of what creates such harsh social divides on this issue.

Add To Your Calendar

Set a reminder on your calendar for the Jan 6 ZeroHedge debate, airing on this website and on X, on January 6, 2024 at 7:00pm EST. We will also dedicate a portion of the debate to responding directly to questions submitted by our premium subscribers.

https://www.zerohedge.com/markets/save-date-media-titans-clash-live-no-holds-barred-january-6-debate

AlloVir shedding 95% of its staff after discontinuing T cell therapy trial

 AlloVir Inc. (ALVR), a developer of cell therapies intended to treat viral diseases, said Thursday that its board had approved a roughly 95% reduction to its staff, following an announcement last month that it would discontinue three clinical trials on its lead T cell therapy posoleucel. The company, in a filing, said the board approved the cuts on Jan. 1, and that the cuts were intended to "preserve capital." The employee dismissals were set to take place largely in the first quarter of 2024 and would largely be done by April 15. Last month, AlloVir said it would discontinue its Phase 3 trials of posoleucel, a therapy intended to target six viral pathogens, including the Epstein-Barr virus and human herpesvirus. At that time, the company said an analysis concluded that "the studies were unlikely to meet their primary endpoints." AlloVir, in the filing on Thursday, said it expected to book charges of around $13 million, largely in the first quarter, to account for severance and other benefits. Shares were up 3.4% in after-hours trade.

https://www.morningstar.com/news/marketwatch/202401041038/allovir-shedding-95-of-its-staff-after-discontinuing-t-cell-therapy-trial

Xeris Biopharma Updates Its Outlook for 2023

 Company expects to be cashflow positive for the fourth quarter, report total revenue at the high end of its previous guidance of $160M-$165M, and end 2023 with over $72M in cash, cash equivalents, and short-term investments, exceeding its previous guidance of $65M-$70M

Company to report Q4 and FY 2023 financial results on or about March 6, 2024

https://www.businesswire.com/news/home/20240104585894/en/

InflaRx Announces Positive Topline Results in Phase 1 Antiinflamatory Study

 

  • MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days:
    • Achieved ≥90% blockade of C5a-induced neutrophil activation over 14-day dosing period
    • Achieved favorable concentration-time profiles with target exposures of therapeutic potential
    • Well tolerated with no safety signals of concern over entire dose range
  • Company to advance INF904 into Phase II clinical development
  • Company to host a conference call today, January 4, 2024 at 8:30 a.m. EST/14:30 CET

InflaRx will host a conference call today, January 4, 2024 at 8:30 a.m. EST (14:30 CET) to provide more details about the announced topline results of the MAD part of its Phase I study of INF904 in healthy human subjects. To participate in the conference call, participants may pre-register here and will receive a dedicated link and dial-in details to easily and quickly access the call. A replay will be available on the InflaRx website in the Investors – Events & Presentations section after the live conference call has concluded.

InflaRx’s management team will host investor and business meetings during JPM Week from January 8 to 11, 2024 in San Francisco, California.

https://www.globenewswire.com/news-release/2024/01/04/2803830/0/en/InflaRx-Announces-Positive-Topline-Results-from-the-Multiple-Ascending-Dose-MAD-Phase-I-Study-with-C5aR-Inhibitor-INF904.html

Avanos Prelims; Revises Preliminary 2024 Revenue Outlook

 For the fourth quarter ended December 31, 2023, Avanos Medical, Inc. (the "Company") expects net sales in the range of $170 million to $173 million, a decrease of approximately 6.5% to 4.5% compared to the same period in 2022, with net sales for the year ended December 31, 2023 anticipated to be in the range of $670 million to $673 million.

Net sales for the fourth quarter were lower than expected due to:

  • Underperformance by the Company's hyaluronic acid ("HA") pain relief injection products, primarily as a result of continued pricing pressure due to the Medicare reimbursement changes. The Company estimates that net sales for the HA product line will be slightly above $10 million for the fourth quarter of 2023, which is approximately $4 million lower than anticipated.
  • Lower than anticipated sales across the Company's North America Digestive Health products, primarily due to a major distributor's ordering pattern change.
  • North America Pain Management and Recovery sales, while improved, were below internal expectations.

The Company anticipates that the lower than expected net sales will negatively impact adjusted gross margin, adjusted EBITDA margin and adjusted earnings per share for the fourth quarter and the full year. The Company is currently unable to quantify the overall impact on these measures.

"Although we are disappointed with our fourth quarter sales results, we were pleased with the execution of our three- year transformation initiative throughout 2023, which we believe positions us strongly for 2025," stated Joe Woody, Avanos' chief executive officer. "We are maintaining the 2025 financial objectives that we laid out at our Investor Day in June, and I look forward to updating investors on our overall progress next Monday at the JP Morgan Healthcare Conference."

Revised Preliminary 2024 Revenue Outlook

The Company is updating its previous revenue guidance for the year ending December 31, 2024. For 2024, the Company now expects net sales in the range of $685 million to $705 million, reflecting continued HA market dynamics. The Company will provide additional information regarding its outlook for 2024 on the conference call it will host to discuss its financial results for the quarter and year ended December 31, 2023, which is currently scheduled for February 20, 2024.

The Company does not plan to release preliminary financial information on an ongoing basis. The financial information presented above is preliminary, is based on information available to management as of the date of this press release, and is subject to further changes upon completion of the Company's standard quarter and year-end closing procedures. This update does not present all necessary information for an understanding of the Company's financial condition as of the date of this press release or its results of operations for the quarter and year ended December 31, 2023. As the Company completes its quarter-end and year-end financial close processes and finalizes its financial statements for the quarter and year ended December 31, 2023, it will be required to make significant judgments in a number of areas. It is possible that  the Company may identify items that require it to make adjustments to the preliminary financial information set forth above and those changes could be material. The Company does not intend to update such financial information prior to release of its financial statement information for the quarter and year ended December 31, 2023, which is currently scheduled for February 20, 2024.

https://www.prnewswire.com/news-releases/avanos-medical-inc-reports-preliminary-fourth-quarter-and-full-year-2023-financial-results-revises-preliminary-2024-revenue-outlook-302026023.html